| Date | Title | Description |
| 09.06.2026 | Открытое использование (public domain): когда истекает патент и как работать с общественным достоянием | Патент — это временная монополия. Государство даёт изобретателю исключительное право на коммерческое использование технологии в обмен на ее публичное раскрытие. Когда срок действия данного права истекает, технология переходит в общественное... |
| 26.02.2026 | Slate Medicines Secures $130M to Advance Migraine Prevention | Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach... |
| 24.02.2026 | Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine Therapies | Slate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a... |
| 06.06.2025 | JPMorgan’s top biotech and pharma picks for the second half | - |
| 28.04.2025 | Фармрынок идет на поправку | - |
| 15.04.2025 | Назад, в генетическое будущее | - |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 25.03.2025 | Daniel Pierce Joins Initial Therapeutics as Chief Scientific Officer | SOUTH SAN FRANCISCO, Calif., March 24, 2025 — Initial Therapeutics, a life sciences
company discovering and developing new small-molecule therapeutics with a novel
platform to selectively modulate translation of pathogenic proteins by the r... |
| 25.03.2025 | Daniel Pierce Joins Initial Therapeutics as Chief Scientific Officer | SOUTH SAN FRANCISCO, Calif., March 24, 2025 — Initial Therapeutics, a life sciences
company discovering and developing new small-molecule therapeutics with a novel
platform to selectively modulate translation of pathogenic proteins by the r... |
| 12.03.2025 | Выпускайте субстанцию: фарма ищет лучшую версию себя | - |
| 20.02.2025 | JPMorgan’s top biopharma picks for 2025 | - |
| 13.02.2025 | FreeOx Biotech Celebrates Landmark 2024 with Record Growth: New Hires, Groundbreaking Trial Selections, and Major Funding Milestones | FreeOx Biotech
Innovative Biotech Company Expands Executive Team with Three C-Suite Appointments and Advances Pipeline with Key Trial Evaluations
BARCELONA and PALO ALTO, Feb. 13, 2025 /PRNewswire-PRWeb/ -- FreeOx Biotech, a clinical-stage ... |
| 02.08.2024 | Kexing Biopharm's Apexelsin®: A New Dawn in Cancer Treatment | In a significant stride for cancer treatment, Kexing Biopharm has secured European Commission approval for Apexelsin®, a generic version of the well-known drug Abraxane® (Nab-paclitaxel). This approval, announced on July 28, 2024, marks a p... |
| 31.07.2024 | Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval | SHENZHEN, China, July 31, 2024 /PRNewswire/ -- On July 28 2024, Kexing Biopharm announced European Commission approval of Apexelsin®, the generic drug to Bristol Myers Squibb's and Celgene's Abraxane®(Nab-paclitaxel). Apexelsin® is develope... |
| 24.04.2024 | Govt expands committee for drugs, medical devices pricing reforms | - |
| 15.04.2024 | Women of Influence: Health Care 2024 – Ileana Hernandez | - |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID19 Pandemic Top Players Industry Trends and Forecast 2032 | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭. This comprehen... |
| 25.10.2021 | Nereid Therapeutics Announces Appointments of Laura Forese and Rupert Vessey to Its Board of Directors | BOSTON, Oct. 25, 2021 /PRNewswire/ -- Nereid Therapeutics, a company discovering new disease treatments by applying pioneering research and technologies in biomolecular condensates, announces the appointment of Laura L. Forese, M.D., MPH, a... |
| 21.10.2021 | ATP Names Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology | NEW YORK and LONDON, October 21, 2021/PR NEWSWIRE/ – ATP, a leader in life sciences venture capital, announced today the appointment of Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology. In this role, Dr. Chopra is responsible for... |
| 16.11.2020 | Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field | BOSTON, November 16, 2020/PR NEWSWIRE/ -- Apple Tree Partners (ATP), a leading life sciences venture firm, today announced the launch of Nereid Therapeutics, a company dedicated to discovering new disease treatments by applying pioneering r... |
| 12.11.2020 | British biopharmaceutical company Grow Group PLC announces GBP 6 million Series C fundraise for cannabis market expansion
USA - English
Deutschland - Deutsch
France - Français | |
| 16.01.2020 | Clinical-Stage Biopharmaceutical Company Tarsus Pharmaceuticals Receives $60 Million | Clinical-stage biopharmaceutical company Tarsus Pharmaceuticals announced it raised $60 million in Series B funding led by Vivo Capital
Tarsus Pharmaceuticals — a clinical-stage biopharmaceutical company — announced that it raised $60 milli... |
| 21.10.2019 | Olivia Zollinger becomes the first CEO of Swiss Healthcare Startups | |
| 13.09.2019 | Anokion raises $40 million and acquires US biotech startup | |
| 26.08.2019 | Celgene to sell psoriasis drug to Amgen for $13.4B, clearing key hurdle to BMS deal | Shares of Celgene were up 3.7 percent in premarket trading on the Nasdaq Monday following the announcement. The company’s stock remained up about 3.7 percent after markets opened. Shares of BMS were up about 4 percent on the New York Stock ... |
| 16.07.2019 | Celgene Exercises Commercial Option for Zymeworks’ Azymetric™ Platform Triggering $7.5MM Milestone Payment | VANCOUVER, British Columbia–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has sel... |
| 17.05.2019 | Four years after EU approval, NICE finally backs Revlimid use in certain first-line multiple myeloma patients | Four years after the European Commission sanctioned the use of Celgene’s flagship Revlimid to treat adults with previously-untreated multiple myeloma who are not eligible for transplant, England’s National Health Ser... |
| 22.04.2019 | Poseida raises $142M in Series C round to advance multiple myeloma CAR-T, preclinical cell therapies | The company’s lead product candidate is P-BCMA-101, an autologous CAR-T that targets the BCMA antigen in the blood cancer multiple myeloma. It is currently in a registration-directed Phase II clinical trial that is recruiting patients.
“We ... |
| 18.04.2019 | Osage University Partners and Celgene Corp. Lead $75M Series B For Arrakis Therapeutics | WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, has completed a $75 million Series B financing co-led by venBio... |
| 11.04.2019 | Asklepios BioPharmaceutical Receives $235M in Funding | Asklepios BioPharmaceutical, a developer and manufacturer of Adeno-Associated Virus (AAV) gene therapy therapeutics for underserved patient populations with rare and generally untreatable genetic disorders, raised $235m in funding.
TPG Capi... |
| 08.04.2019 | Celgene, Acceleron submit FDA application for billed blockbuster luspatercept — will they get priority review? | Celgene and their partners at Acceleron are counting on their red blood cell boosting drug to win a speedy review as they submitted a marketing application for the biologic on Friday. For the big biotech — tarnished by a p... |
| 08.04.2019 | Celgene, Acceleron file for approval of blood disease drug luspatercept | In a note to clients Sunday, Cowen analyst Yaron Werber wrote that the filing was in line with expectations, and approval is expected in April 2020. While Cowen anticipates a regular review, there is also a “good probability” that the FDA w... |
| 05.04.2019 | Bayer reports cyber attack pointed to Chinese hackers; FDA prolongs review of Daiichi Sankyo's AML drug | → Bayer has stopped a cyber attack in its tracks, the company said, seemingly without having any data stolen or compromising third-party personal data. The German drugmaker suspects that the infectious software — whi... |
| 13.03.2019 | Celgene's chemotherapy Abraxane stumbles in pivotal pancreatic cancer study | Days after Celgene’s Abraxane secured approval in combination with Roche’s checkpoint inhibitor for frontline use in triple negative breast cancer, the US drugmaker reported that the chemotherapy failed to improve prog... |
| 13.03.2019 | Celgene’s Abraxane flops in pivotal pancreatic cancer study | Cannacord analysts John Newman and Christopher Liu wrote that because pancreatic cancer is a very difficult cancer to treat, they considered any extension in overall survival to be meaningful. Abraxane has FDA approval for metastatic breast... |
| 11.03.2019 | Is second time the charm for ozanimod? Celgene starts to find out with EMA filing | Celgene has officially embarked on ozanimod’s comeback regulatory journey, submitting an application to the EMA days before it plans to knock on the FDA’s door — just in time for the deadline it has set for itself.
Jay ... |
| 07.01.2019 |
NantCell Receives $30M More From Celgene, Now A $4 Billion Unicorn
| Los Angeles-based NantCell, one of the biotech companies run by billionaire Dr. Patrick Soon-Shiong, has raissed another $30M from Celgene, according to the two companies. According to NantCell, it has now raised a total of $105M from Celge... |
| 06.01.2019 | Celgene adds $30 million to investment in Soon-Shiong firm NantCell | Drugmaker Celgene Corp. agreed to invest an additional $30 million in a cancer-fighting start-up that’s majority owned by Los Angeles biotech entrepreneur Dr. Patrick Soon-Shiong, the companies said Friday.
Celgene’s second-round funding wo... |
| 08.10.2018 | New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism | - |
| 23.09.2018 | Celgene Joins $47.5M Series A for Silverback Therapeutics | Silverback Therapeutics, Inc., a biotechnology company developing a pipeline of systemically delivered, locally active therapies, has closed an extension of its Series A financing to bring the total raised in the round to $47.5 million. The... |
| 30.05.2018 | J&J to enter Chinese CAR-T for myeloma into Phase Ib/II trial | The CAR-T was originally developed by Nanjing, China-based Legend, under the development name LCAR-B38M. Janssen announced in December that it had paid Legend $350 million upfront for a worldwide licensing agreement for the therapy. The Chi... |
| 25.05.2018 | FDA: Drugmaker ‘shenanigans’ delaying cheaper competitors and boosting prices | The FDA listed more than 50 drugs whose manufacturers have withheld or refused to sell samples, and cited 164 inquiries for help obtaining them. Thirteen of these pleas from makers of generics pertained to Celgene’s blockbuster cancer drug ... |
| 06.03.2018 | Gene therapy had banner year in 2017 with 164% funding boost to $4.5 billion | The approvals include those for the CAR T-cell therapies Kymriah developed by Novartis that won FDA approval in August. And in October, FDA blessed Kite Pharma for Yescarta that Gilead acquired.
“These groundbreaking product approvals and c... |
| 01.02.2018 | Is too much money being invested in oncology? | Oncology is to funding as gravity is to everything else – but is it over the top? Is cancer investment too much, too little or just right?
“I’ve been asking this for a number of years,” said Jay Lichter, managing director at Avalon Ventures... |
| 22.01.2018 | Anatomy of two biotech deals worth $20B | Celgene snags Juno Therapeutics for $9 billion
Background: Celgene is one of the hungriest biotechs in the M&A game, with a clear need for late-stage assets to replenish its oncology and autoimmune pipeline. Its revenues have been incre... |
| 22.01.2018 | Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy | - |
| 22.01.2018 | Celgene Corporation to Acquire Juno Therapeutics | |
| 07.01.2018 | Developing a Sanofi cast-off, Impact Biomedicines now subject of $7B Celgene acquisition deal | A startup developing the once-discarded fedratinib, a drug cast off from Sanofi due to safety concerns back in 2013, is now the subject of a $7 billion acquisition deal by Celgene.
John Hood
The tiny San Diego company at t... |
| 04.01.2018 | Akiri to Create First Network-as-a-Service Platform Optimized for Healthcare | San Fran-based Akiri launched with plans to bring the first network-as-a-service (NaaS) platform to the healthcare industry . Its first product Akiri Switch (formerly known as Health2047 SwitchCo) will be a subscription-based data network t... |
| 21.12.2017 | Celgene, GV-backed FLX gets off $60M round, kick-starts I-O trials | FLX Bio has boosted its cash supplies with a new $60 million series C round as it starts dosing for its new cancer test.
South San Francisco, California-based FLX emerged from Bristol-Myers Squibb’s $800 million takeover of Flexus Bioscienc... |
| 26.10.2017 | In a pre-Halloween fright show, Celgene just scared the hell out of Wall Street — shares crater | For years now Celgene has impressed analysts and wowed investors with aggressive revenue growth and one of the most ambitious R&D efforts in biotech. But after alarming Wall Street with a major fail for one of its big Phas... |
| 06.07.2017 | Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table | Celgene is joining the fast growing PD-1 club.
John Oyler, BeiGene
The big biotech $CELG has taken a lead position in the second wave of PD-1 checkpoints in the clinic, bagging rights to BeiGene’s $BGNE candidate for solid tum... |
| 27.02.2017 | Pfizer and Celgene Join $38M Series A For Arrakis Therapeutics | WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a pioneering biopharmaceutical company, has completed a $38 million Series A financing led by Canaan Partners with participation by Advent Life Sciences, Pfizer Inc., Celgene Corporatio... |
| 15.02.2017 | Versant finishes Fund V with $20M NASH startup | As far as startups go, the bet looks relatively safe. Jecure’s executive team is proven and familiar. CEO Jeffrey Stafford and CSO James Veal led the team at Quanticel Pharmaceuticals, a 2010 genomics startup hand-raised by Versant.
Celgene... |
| 26.01.2017 | Celgene acquires autoimmune startup Delinia for $775M | As recently as September 2016, Delinia was a fledgling autoimmune startup, launching with just four full-time staff and a $35 million Series A co-led by Sofinnova Partners and Atlas Venture.
Five months later it’s a very different story.
Au... |
| 26.01.2017 | Celgene scoops up freshman autoimmune startup Delinia in $775M buyout | Four months ago, Atlas Venture partner Saurabh Saha set up shop at the newborn Delinia with a preclinical autoimmune drug, $35 million in startup cash and a skeleton crew. Today, Celgene says it struck a deal to buy the start... |
| 30.11.2016 | Bluebird bio announces positive CAR-T results | Just over four months ago, the FDA put a temporary hold on the same Phase 2 ROCKET trial after two patients died of cerebral edema, the same cause of death in last week’s announcement. The FDA gave the all-clear five days later and allowed ... |
| 01.11.2016 | Digital health deals: Virgin Pulse, Fitbit partner for employee wellness program and more | Fitbit has partnered with Virgin Pulse, a mobile-first employee wellness and engagement company, to offer Fitbit trackers at a lower cost and develop personalized wellbeing programs around Fitbit’s Group Health offerings. The collaboration ... |
| 08.08.2016 | Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study | Can a 4-cylinder biotech with an unconventional development partner help drive a largely unknown cancer drug through Phase III on an industry track dominated by world famous Formula One teams? San Diego-based MEI Pharm... |
| 19.07.2016 | Celgene backs next-gen oncolytic virus startup in $57M Series A | Newly unveiled Oncorus has raised a $57 million Series A to back its efforts to use next-gen oncolytic viruses to treat aggressive cancers including a type of brain cancer, glioblastoma multiforme (GBM). Active strategic investor Celgene ($... |
| 05.04.2016 | Daily funding roundup - April 5, 2016 | Human Longevity bagged $220M Series B; Persado closed $30M; Sequoia Capital invested in Mintigo
London-based on-demand delivery company Jinn closed a $7.5 million Series A round of funding, according to TechCrunch, led by Samaipata Ventures... |
| 30.04.2015 | CRISPR Therapeutics Raises Additional $64 Million | |
| 21.01.2015 | Celgene, Biotech's Ace Dealmaker, Bets On Canada's Zymeworks | Celgene, the big maker of blood cancer drugs, has gained a reputation for anointing biotech startups before they break out. Now it’s betting on a little Canadian biotech, Zymeworks, with technology for engineering new types of targeted anti... |
| 31.01.2014 | East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
[Updated, 8:44 am ET] Local biotechs were out for cash this week. One company saw its share price triple in its first day on the Nasdaq. Three others lined up stock offerings.... |
| 07.10.2013 | PharmAkea Therapeutics Raises Series A Financing | PharmAkea Therapeutics, Inc., a San Diego, CA-based developer of a drug discovery platform to generate and advance novel small-molecule therapies targeting cancer and fibrotic diseases, raised 10m in Series A financing from Bay City Capital... |
| 31.08.2012 | Former court foes Penn and pharma company forge cancer therapeutics licensing deal | “Agios Pharmaceuticals and The University of Pennsylvania (“Penn”) today announced that, in connection with the resolution of litigation announced earlier today, Agios and Penn have entered into a licensing agreement involving new intellect... |
| 23.07.2012 | Late-stage cystic fibrosis, muscular dystrophy drug raises $30 million | With cystic fibrosis the goal is to improve lung function and reduce pulmonary exacerbation. In a Phase 3 clinical study, Ataluren demonstrated trends in improvement in lung function when compared to a placebo. There were also trends in imp... |
| 21.06.2012 | Celgene’s multiple myeloma drug setback in Europe gets mixed response | Sanford Bernstein analyst Geoffrey Porges criticized the company’s management in a Forbes article for what he said was the company’s bullishness.
“Owning this stock is like Bill Murray in Groundhog Day … the same bad experiences over and ov... |
| 26.04.2012 | Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration | Celgene also has a phase 3 trial under way that is using the Abraxane in the treatment of metastatic pancreatic cancer with data expected in the second half of 2012 or the first half of 2013. It has at least six late-stage clinical trials u... |
| 09.04.2012 | Celgene in strategic discovery deal with therapeutic antibody firm | Celgene (NASDAQ:CELG) has agreed to a strategic discovery deal with a company that is developing antibodies to combat multiple diseases in Celgene’s latest move to diversify its portfolio.
AnaptysBio uses a proprietary platform that replica... |
| 10.02.2012 | Startupalooza highlights digital health companies: Epion Health | Startupalooza NJ is a competition in which technology, digital health and medical device companies competed for the chance to present their products before a wider audience of private equity investors in New York next month. This is one of ... |
| 09.02.2012 | Celgene invests $15 million for closer collaboration with cancer drug co. | Walter C. Ogier, Acetylon’s president and chief executive officer, said in a company statement:
“The potential synergistic combination of Celgene’s class-leading myeloma drug, Revlimid, with Acetylon’s selective HDAC6 inhibitor, ACY-1215, i... |
| 09.02.2012 | Acetylon Pharmaceuticals Receives $15M Investment from Celgene | Acetylon Pharmaceuticals, a Boston, MA-based developer of small molecule drugs to realize the therapeutic potential of HDAC inhibition to treat cancer, autoimmune and other diseases, has received a $15m investment from Celgene Corporation (... |
| 09.02.2012 | Acetylon Pharmaceuticals Raises $15M |
BOSTON, MA, Acetylon Pharmaceuticals announced that Celgene Corporation (NASDAQ: CELG) will invest a total of $15 million in Acetylon via the purchase of Series B-2 Preferred Stock.
>> Click here for more funding data on Acetylon P... |
| 03.02.2012 | At Bio NJ, Gov. Chris Christie takes on Snooki, losing chief of staff to pharma | A report published last month by the HealthCare Institute of New Jersey said the pharmaceutical and medical device industry paid $731 million in taxes to the state in 2010.
Christie said promoting the life sciences industry is one of four p... |
| 26.01.2012 | Celgene cancer drug acquisition may bode well for life science M&A | Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached.
Avila’s therapeutic platform involves the development of covalent drugs, which latch onto or bond with ... |
| 23.12.2011 | Acceleron Pharma Raises $30M in Funding | Acceleron Pharma, Inc., a Cambridge, MA-based biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, has raised $30m in funding.
Backers include Celgene and all other existing investors.
The company intend... |
| 17.11.2011 | Agios Pharmaceuticals Raises $78M in Series C Financing | Agios Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, has secured $78m in Series C financing.
Backers include three new large p... |
| 28.10.2011 | Earnings roundup: Bristol-Myers Squibb and Celgene | Among the drugs in the pipeline are a new blood clot preventer called Eliquis developed with Pfizer and dapagliflozin for type 2 diabetes — the FDA has delayed making a decision until January next year.
Still, its research, marketing and ta... |
| 12.01.2010 | VentiRx Pharmaceuticals Raises $25M in Series A Extension Financing | VentiRx Pharmaceuticals, Inc., a San Diego, CA-based biopharmaceutical company focused on the development of candidates for the treatment of cancer, respiratory and inflammatory diseases, completed a $25m Series A Extension.
The extension w... |
| 12.01.2010 |
VentiRx Gets $25M In Series A Extension
| San Diego-based biopharmaceuticals firm VentiRx Pharmaceuticals said today that the firm has raised $25M in a Series A extension round. The firm, which is developing treatments for cancer, respiratory, and inflammatory disease, said the rou... |
| 07.10.2009 | Schering-Plough launches schizophrenia, bi-polar disorder drug after buying maker | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 26.08.2009 | USA, Gloucester Pharmaceuticals closed a $29m series D financing | Gloucester Pharmaceuticals raised $29m in a Series D financing led by new investor Novo Ventures and included current investors Apple Tree Partners, ProQuest Investments, Prospect Venture Partners and Rho Ventures.The proceeds will be used ... |
| 05.11.2008 | Ferrokin brings in $8.4M for anemia treatment | Ferrokin Biosciences, a San Carlos Calif. company that makes compounds to treat iron overload in patients with anemia, received $8.4 million of what it hopes will be a $15 million first-round of funding from Clarus Ventures, Burrill & C... |
| 06.03.2007 |
VentiRx Raises $28.9M
| San Diego-based VentiRx Pharmaceuticals announced today that it has raised $28.9M in funding for the firm's treatments for cancer and infection, respiratory, and autoimmune diseases. The funding came from Frazier Healthcare Ventures, ARCH V... |
| - | Schering-Plough launches schizophrenia, bi-polar disorder drug after buying maker | CLEVELAND, Ohio – Sometimes acquiring other drugmakers is the way to fill your company’s development pipeline with new drugs.
Fred Hassan, chairman and chief executive of Schering-Plough Corp., told attendees of the Cleveland Clinic’s 2... |
| - | Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration | Celgene (NASDAQ:CELG) has submitted a new drug application to the U.S. Food and Drug Administration for pomalidomide, a drug designed for multiple myeloma that does not respond to therapies.
Since the drug is for an unmet need, the company ... |
| - | Versant finishes Fund V with $20M NASH startup | San Diego, California-based Jecure officially debuted on Wednesday, bringing a new platform and research approach to the silent epidemic of liver fibrosis and non-alcoholic steatohepatitis (aka NASH) — a type of fatty liver disease.
Versant... |
| - | Bluebird bio announces positive CAR-T results | The CAR-T field can rest a little easier, reassured by Wednesday’s positive interim results from bluebird bio’s Phase 1 dose escalation study for an anti-BMCA CAR-T in relapsed/refractory multiple myeloma.
The news comes just one week after... |
| - | Celgene to sell psoriasis drug to Amgen for $13.4B, clearing key hurdle to BMS deal | Drugmaker Bristol-Myers Squibb and biotech company Celgene have found a buyer for a Celgene drug that had stood in the way of the former’s acquisition of the latter.
New York-based BMS said Monday that Celgene had agreed to sell the psorias... |
| - | Celgene cancer drug acquisition may bode well for life science M&A | Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached.
Avila’s therapeutic platform involves the development of covalent drugs, which latch onto or bond with ... |
| - | Startupalooza highlights digital health companies: Epion Health | Startupalooza NJ is a competition in which technology, digital health and medical device companies competed for the chance to present their products before a wider audience of private equity investors in New York next month. This is one of ... |
| - | Celgene acquires autoimmune startup Delinia for $775M | On Thursday, Summit, New Jersey-based Celgene Corporation announced plans to acquire Delinia for an upfront $300 million and an additional $475 million in milestone-based payments. The transaction is expected to close in the first quarter o... |
| - | Celgene in strategic discovery deal with therapeutic antibody firm | Celgene (NASDAQ:CELG) has agreed to a strategic discovery deal with a company that is developing antibodies to combat multiple diseases in Celgene’s latest move to diversify its portfolio.
AnaptysBio uses a proprietary platform that replica... |
| - | FDA: Drugmaker ‘shenanigans’ delaying cheaper competitors and boosting prices | Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaise... |
| - | Celgene’s multiple myeloma drug setback in Europe gets mixed response | Celgene’s (NASDAQ:CELG) move to withdraw its multiple myeloma drug Revlimid new application submission from the Committee for Medicinal Products for Human Use was a setback for the drug developer. But the significance of the setback was a m... |
| - | Anatomy of two biotech deals worth $20B | Analysts had forecast a blockbuster year for life science mergers and acquisitions as the lower tax rate for repatriated cash kicks-in and Big Pharma continues its hunt for late-stage assets.
It seems the predictions may be coming true. Cel... |
| - | At Bio NJ, Gov. Chris Christie takes on Snooki, losing chief of staff to pharma | New Jersey Gov. Chris Christie held forth at the New Jersey biotechnology association NJ Bio annual meeting last night on a range of topics from Snooki’s tweets about him to the recent return of his chief of staff Richard Bagger to the phar... |
| - | Poseida raises $142M in Series C round to advance multiple myeloma CAR-T, preclinical cell therapies | A Swiss drugmaker that markets one of the two approved CAR-T cell therapies has led the latest financing of a company developing CAR-Ts of its own.
San Diego-based Poseida Therapeutics said Monday that it had closed a $142 million Series C ... |
| - | Celgene invests $15 million for closer collaboration with cancer drug co. | Celgene (NYSE:CELG) has made a $15 million strategic investment in a cancer drug developer, which gives it a seat on the company’s board and opens up collaboration opportunities down the road.
Acetylon Pharmaceuticals uses histone deacetyla... |
